Comment
doi: 10.1161/STROKEAHA.117.016603.
Epub 2017 Mar 10.
Response by Hänggi and Macdonald to Letter Regarding Article, "Randomized, Open-Label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage])"
Affiliations
- PMID: 28283608
- DOI: 10.1161/STROKEAHA.117.016603
Item in Clipboard
Comment
Response by Hänggi and Macdonald to Letter Regarding Article, "Randomized, Open-Label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage])"
Stroke.
2017 Apr.
No abstract available
Comment on
-
Randomized, Open-Label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage]).Stroke. 2017 Jan;48(1):145-151. doi: 10.1161/STROKEAHA.116.014250. Epub 2016 Dec 8. Stroke. 2017. PMID: 27932607 Free PMC article. Clinical Trial.
-
Letter by Rustemi Regarding Article, "Randomized, Open-Label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage])".Stroke. 2017 Apr;48(4):e113. doi: 10.1161/STROKEAHA.116.016512. Epub 2017 Mar 10. Stroke. 2017. PMID: 28283604 No abstract available.